Editorials

<< Previous   of   Next >>   ADVERTISEMENT   HAVE YOUR SAY Feel strongly about something? Share it with the community by writing a letter to the editor. You’ll need to include your name, address and daytime phone number. (We’ll only publish your name and hometown.) We reserve the right to edit letters, but if you keep yours to 250 words or less, we won’t ask you to shorten it. If your letter is published, please wait 30 days before submitting another. Send it to: E-mail: letters@heraldnet.com Mail: Letters section The Herald P.O. Box 930 Everett, WA 98206 Fax: 425-339-3458 Have a question about letters? Contact Carol MacPherson (cmacpherson@heraldnet.com or 425-339-3472).   Published: Tuesday, April 1, 2008 Approving medicines shouldn't be a rush job What do Americans get in addition to paying the highest prices in the world for prescription drugs? The real possibility that if the expensive prescription drug was approved on deadline, it just may cause safety problems down the line. Like what happened with the drugs Vioxx, Bextra, Rezulin and Baycol -- all taken off the market. Harvard researchers recently found that medicines approved right on deadline by the FDA are more likely to cause safety problems than those given the OK with time to spare. Their study was published in the New England Journal of Medicine. The FDA disputes the findings. "The article is a wake-up call," said Dr. Steven Nissen, the Cleveland Clinic's influential cardiology chief. "It puts the FDA in a very difficult situation when they're trying to make complex decisions under these very, very tight deadlines," he told the Associated Press. "We've got to re-evaluate now whether that's good public policy." Well, our quick re-evaluation says no, it's not good public policy to rush drugs to market, for the sake of profit, with patients as guinea pigs. According to the AP, deadlines were first imposed on the FDA by a 1992 law that allowed drug makers to pay millions of dollars in fees directly to the cash-strapped agency so it could hire more reviewers and clear a backlog of pending drug applications. In return, the FDA had to either approve or reject 90 percent of all drug candidates within 12 months of their application, or lose money. The deadline was six months for drugs so novel or potentially lifesaving to be classified high-priority. Congress tightened the deadline for most drugs to 10 months in 1997. The Harvard researchers found approval is 3.4 times as likely in the two months leading up to the user-fee deadline as at any other time. Drugs approved in that just-before-deadline period had a four- to five-fold higher rate of later being withdrawn or requiring serious safety warnings, compared with drugs approved faster -- presumably slam-dunks -- or those that miss the deadline, Harvard professor Daniel Carpenter concluded. The researchers rechecked their numbers after the FDA objected, and stood by their findings. It takes big-time side effects to get a drug pulled: Vioxx was taken off the market in 2004 for increasing the risk of heart attacks and strokes. The diabetes drug Rezulin was withdrawn in 2000 for causing liver problems. The Harvard researchers clearly show that our hurry-up-and-make-money system for approving new drugs can put Americans' health at risk. It's a policy that makes no sense, medically or morally.

1. Good grief! 2. Swine flu lingers, making traditional flu season unpredictable 3. Two vie to serve as Snohomish County prosecutor 4. Last hurrah for Huskies’ Locker? 5. Koster for Congress? He’s still undecided 6. Here’s how home foreclosure sales really work 7. A store credit card can save you cash, but is it worth it? 8. New site sought for Snohomish pool project 9. Families get an early gift: free Christmas trees 10. Prep Roundup: Lake Stevens wins two wrestling meets 2 - Top 10 Stories Most Talked about 3 - Top 10 Stories Most Emailed

• Wildcats fall to familar foe in semis • ‘Nutcracker' times three • Road warrior • Mavericks reloading • Holiday Lightings & Santa Sightings • Cities prepare for winter blast repeat • Wolfpack duo takes last shot at state tourney • This Weekend in Your Town • Tips for the stormy season • Boeing will build, flight test and deliver 787s in South Carolina to spe ... • Snohomish County EDC promoting job growth in key industry clusters • $4 million grant to advance brain tumor research has Everett links • Providence medical center construction tops off its 12-story steel frame ... • Tulalip affordable housing project to be financed by KeyBank, Raymond Ja ... • Arlington's Lak of Ink has a growing following for Luke Kooyman's creati ... • Bank of the Northwest formed • Cascade Bank earns $1.6 million